MajesTEC-4

About this trial

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Patient Profile

Patients with newly diagnosed multiple myeloma

Where’s this trial being run?

Beaumont Hospital, University Hospital Limerick, and University Hospital Galway

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	MajesTEC-4
Number:	23-21
Full Title:	Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4)

Principal Investigator:	Dr Janusz Krawczyk
Type:	Industry Sponsored
Sponsor:	Janssen
Recruitment Started:	Global: 08-Sep-2022 Ireland:

Global Recruitment Target:	Approx. 1500 patients
Ireland Recruitment Target:	17 patients